By mid-2026, the industry has officially entered the era of "Targeted Recruitment." This year, the focus is on a critical re-evaluation of FXR agonists like cilofexor. Despite a disappointing Phase 3 result in late 2025 where it missed its primary fibrosis endpoint, researchers in 2026 are using AI-driven patient stratification to identify sub-groups—specifically those with early-stage...
English
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Greek